<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02554136</url>
  </required_header>
  <id_info>
    <org_study_id>HM-ROMA-105</org_study_id>
    <nct_id>NCT02554136</nct_id>
  </id_info>
  <brief_title>Evaluating a Pharmacokinetic Drug Interaction Between HGP0918 and HGP0816</brief_title>
  <official_title>An Open-labeled, Randomized Crossover Study to Evaluate the Pharmacokinetic Interaction and Safety After Single Oral Administration of HGP0918 and HGP0816 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators investigate the potential pharmacokinetic drug-drug interaction between
      HGP0918 and HGP0816 in healthy adult subjects who receive HGP0918 alone, HGP0816 alone, and
      both together in a 3 period repeatedly
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>baseline-corrected Cmax of HGP0918</measure>
    <time_frame>-20, -16, -12, 0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72hr (Total 16)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>baseline-corrected AUCt of HGP0918</measure>
    <time_frame>-20, -16, -12, 0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72hr (Total 16)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of HGP0816</measure>
    <time_frame>0(predose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72hr (Total 13)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt of HGP0816</measure>
    <time_frame>0(predose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72hr (Total 13)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of HGP0918</measure>
    <time_frame>-20, -16, -12, 0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72hr (Total 16)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt of HGP0918</measure>
    <time_frame>-20, -16, -12, 0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72hr (Total 16)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of HGP0918</measure>
    <time_frame>-20, -16, -12, 0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72hr (Total 16)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2β of HGP0918</measure>
    <time_frame>-20, -16, -12, 0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72hr (Total 16)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC∞ of HGP0816</measure>
    <time_frame>0(predose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72hr (Total 13)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of HGP0816</measure>
    <time_frame>0(predose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72hr (Total 13)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2β of HGP0816</measure>
    <time_frame>0(predose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72hr (Total 13)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of HGP0816</measure>
    <time_frame>0(predose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72hr (Total 13)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vdz/F of HGP0816</measure>
    <time_frame>0(predose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72hr (Total 13)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HGP0918 -&gt; HGP0816 -&gt; HGP0918 + HGP0816</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HGP0816 -&gt; HGP0918 + HGP0816 -&gt; HGP0918</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HGP0918 + HGP0816 -&gt; HGP0918 -&gt; HGP0816</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HGP0918 -&gt; HGP0918 + HGP0816 -&gt; HGP0816</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HGP0816 -&gt; HGP0918 -&gt; HGP0918 + HGP0816</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HGP0918 + HGP0816 -&gt; HGP0816 -&gt; HGP0918</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP0918</intervention_name>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP0816</intervention_name>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP0918 + HGP0816</intervention_name>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have ability to comprehend the objectives, contents of study and property
             of study drug before participating in trial and have willingness to sign of informed
             consent in writing

          -  Healthy male volunteers, aged 19 to 55 years.

          -  The result of Body Mass Index(BMI) is not less than 18.5 kg/m2 , no more than 27.0
             kg/m2

        Exclusion Criteria:

          -  Presence of medical history or a concurrent disease that may interfere with treatment
             and safety assessment or completion of this clinical study, including clinically
             significant disorders in digestive system, neuropsychiatric system, endocrine system,
             liver, cardiovascular system

          -  Someone has a declined liver function and Liver enzyme (AST, ALT or total bilirubin)
             level exceeds more than one and a half times normal upper range

          -  Somenone has a declined kidney function and his eGFR &lt; 60mL/min/1.73m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inje Busan Paik hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2015</study_first_submitted>
  <study_first_submitted_qc>September 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2015</study_first_posted>
  <last_update_submitted>September 17, 2015</last_update_submitted>
  <last_update_submitted_qc>September 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

